学科主题临床医学
Polymorphisms of interferon-inducible genes OAS associated with interferon-alpha treatment response in chronic HBV infection
Ren, Shan1; Yu, Haibin1; Zhang, Hongwei1; Liu, Ying2; Huang, Yanxiang1; Ma, Lina1; Wei, Lai3; Wu, Hao1; Chen, Xinyue1
关键词Hepatitis b Virus (Hbv) Interferon-alpha Hbsag Seroconversion Single Nucleotide Polymorphism (Snp) 2 &Prime -oligoadenylate Synthetase(Oas) 5 &Prime Haplotype
刊名ANTIVIRAL RESEARCH
2011-03-01
DOI10.1016/j.antiviral.2011.01.006
89期:3页:232-237
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy ; Virology
资助者National Eleventh Five-year Science and Technology Major Projects, China ; National High Technology Research and Development Program of China (863Program) ; National Eleventh Five-year Science and Technology Major Projects, China ; National High Technology Research and Development Program of China (863Program)
研究领域[WOS]Pharmacology & Pharmacy ; Virology
关键词[WOS]CHRONIC HEPATITIS-B ; SINGLE-NUCLEOTIDE POLYMORPHISM ; SURFACE-ANTIGEN ; VIRUS-INFECTION ; SYNTHETASE ; MXA ; INDUCTION ; PATHWAY ; HBSAG
英文摘要

\ To evaluate the role of host single nucleotide polymorphisms (SNPs) of 2′,5′-oligoadenylate synthetase (OAS) in predicting IFN response in patients with HBV infection, OAS gene and four SNPs were examined in 363 patients with chronic HBV infection (including 41 patients with HBsAg seroconversion) and 57 healthy controls. One SNP and three haplotypes were identified after adjustment for age, sex, HBV DNA. The frequency of OAS3T/C heterozygotes is 52.2% in responders (R) and 38.2% in non-responders (NR), with an odds ratio (OR) of 1.511 (P=0.018). For complete responders (CR) and NR, the OR reached 2.323(P=0.023). Haplotype analyses revealed significant association between three OAS haplotypes and response to IFN-alpha treatment. Genotype combination and interaction between gene-gene analyses disclosed that there was a positive interaction between OAS2/OAS3 and OAS3/OASL, and the rate of OR was 2.46 (likelihood test. P = 0.004) and 4.46 (likelihood test, P = 0.004), respectively. Our results suggest that OAS gene variations may play an important role in response to IFN-alpha and provide a novel strategy for the resolution of HBV infection. (C) 2011 Elsevier B.V. All rights reserved.

语种英语
所属项目编号2008ZX10002-013 ; 2008ZX10002-004 ; 2006AA02A410
资助者National Eleventh Five-year Science and Technology Major Projects, China ; National High Technology Research and Development Program of China (863Program) ; National Eleventh Five-year Science and Technology Major Projects, China ; National High Technology Research and Development Program of China (863Program)
WOS记录号WOS:000288928000007
引用统计
被引频次:14[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55223
专题北京大学第二临床医学院_北京大学肝病研究所
作者单位1.Capital Med Univ, Beijing Youan Hosp, Beijing 100069, Peoples R China
2.Chinese Acad Med Sci, Natl Lab Med Mol Biol, Inst Basic Med Sci, Peking Union Med Coll,Sch Basic Med, Beijing 100005, Peoples R China
3.Peking Univ, Peoples Hosp, Inst Hepatol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Ren, Shan,Yu, Haibin,Zhang, Hongwei,et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-alpha treatment response in chronic HBV infection[J]. ANTIVIRAL RESEARCH,2011,89(3):232-237.
APA Ren, Shan.,Yu, Haibin.,Zhang, Hongwei.,Liu, Ying.,Huang, Yanxiang.,...&Chen, Xinyue.(2011).Polymorphisms of interferon-inducible genes OAS associated with interferon-alpha treatment response in chronic HBV infection.ANTIVIRAL RESEARCH,89(3),232-237.
MLA Ren, Shan,et al."Polymorphisms of interferon-inducible genes OAS associated with interferon-alpha treatment response in chronic HBV infection".ANTIVIRAL RESEARCH 89.3(2011):232-237.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ren, Shan]的文章
[Yu, Haibin]的文章
[Zhang, Hongwei]的文章
百度学术
百度学术中相似的文章
[Ren, Shan]的文章
[Yu, Haibin]的文章
[Zhang, Hongwei]的文章
必应学术
必应学术中相似的文章
[Ren, Shan]的文章
[Yu, Haibin]的文章
[Zhang, Hongwei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。